

External Quality Assessment Scheme

Throat streptococcal culture Round 1, 2023

Specimens

Please find enclosed 3 lyophilized samples S001, S002 and S003 and vials of rehydration fluid, each 0.5 mL.

Caution

Specimens simulate patient samples and they should be handled in the same way as corresponding samples capable of transmitting infectious disease.

Examinations

Throat streptococcal culture

Storage and use

After arrival, the samples should be stored at +2...8 °C.

1. Let the sample and the rehydration fluid warm up to room temperature.
2. Cut the foil packet open at the end where you can feel the thicker part of the loop.
3. Remove the plastic sheath from the loop. Break the loop shaft off from handle directly into the tube containing warm rehydration fluid (blue cap).
4. Incubate the tube for 30 minutes at +35 ... 37 °C.
5. Check that the black film dissolves completely out of the loop. Shake well and discard the loop.
6. Inoculate appropriate media, plate or slide, by using a swab. Spread on media by using a loop.
7. Incubate and interpret according to the routine procedures followed in your laboratory for streptococcal nasopharyngeal culture.

Result reporting

Please enter the results and methods via LabScala (www.labscala.com). If you cannot find your interpretation or method from the list, please contact the EQA Coordinator. Report to the clinician part will be scored.

S001



S002



S003



2023-02-28

INSTRUCTIONS

Product no. 5140
LQ761523011-013/US
UN3373

Subcontracting: Sample pretesting

If the kit is incomplete or contains damaged specimens, please report immediately to info@labquality.fi.

The results should be reported no later than **March 23, 2023.**

The expected results of the round are published in LabScala in the View Reports section by March 28, 2023.

Inquiries

EQA Coordinator
Jaana Paakkanen
jaana.paakkanen@labquality.fi

Labquality Oy

Kumpulantie 15
FI-00520 HELSINKI
Finland

Tel. + 358 9 8566 8200
Fax + 358 9 8566 8280

info@labquality.fi
www.labquality.com




Client report

	No of participants	No of responded participants	Response percentage
Throat streptococcal culture, March, 1-2023	51	49	96.1 %

Summary

Throat streptococcal culture (5140)




Summary	Own score	Max score	Own success rate	Difference	AVR success rate
Sample S001	4	4	100 %	6.1 %	93.9 %
Sample S002	4	4	100 %	0 %	100 %
Sample S003	4	4	100 %	4.1 %	95.9 %
Average:			100 %	3.4 %	96.6 %

History	Test nr.	Own success rate	Difference	AVR success rate
Round 2022-4	1	91.7 %	-5.9 %	97.6 %
Round 2022-3	1	100 %	3.1 %	96.9 %
Round 2022-2	1	91.7 %	-4.2 %	95.9 %
Round 2022-1	1	100 %	4.4 %	95.6 %
Round 2021-4	1	91.7 %	-3.8 %	95.5 %
Round 2021-3	1	100 %	4.3 %	95.7 %
Round 2021-2	1	100 %	1.8 %	98.2 %
Round 2021-1	1	100 %	6.2 %	93.8 %

Sample S001 | Negative/normal flora

Throat streptococcal culture (5140)

Sample S001 Negative/normal flora



LABORATORY SPECIFIC SCORING TABLE

Finding group	Finding	Clinical significance	Own score	Max score	Own success rate	Difference	AVR success rate
Negative/normal flora	Negative / normal flora	Clinically not significant	4	4	100 %	6.1 %	93.9 %
Total:			4	4	100 %	6.1 %	93.9 %

REPORT TO THE CLINICIAN

Finding group	Finding	Finding count	Significant	Non significant	AVR success rate
Negative/normal flora		49			93.9 %
	<input checked="" type="radio"/> Negative / normal flora	46	3	<input checked="" type="radio"/> 43	
	<input type="radio"/> B-haemolytic streptococcus, sent for referral	2	2		
	<input type="radio"/> B-haemolytic streptococcus, Group C	1	1		
Total:		49			93.9 %


SCORING SUMMARY

Finding group	Finding	Finding score	Max score
Negative/normal flora			4
	Negative / normal flora	4	4
	B-haemolytic streptococcus, sent for referral	0	4
	B-haemolytic streptococcus, Group C	0	4
Total:			4

Sample S002 | Streptococcus pyogenes (group A)

Throat streptococcal culture (5140)

Sample S002 Streptococcus pyogenes (group A)



LABORATORY SPECIFIC SCORING TABLE

Finding group	Finding	Clinical significance	Own score	Max score	Own success rate	Difference	AVR success rate
Streptococcus pyogenes (group A)	Streptococcus pyogenes	Clinically significant	4	4	100 %	0 %	100 %
Total:			4	4	100 %	0 %	100 %

REPORT TO THE CLINICIAN

Finding group	Finding	Finding count	Significant	AVR success rate
Streptococcus pyogenes (group A)		49		100 %
	β-haemolytic streptococcus, Group A	31	31	
	● Streptococcus pyogenes	18	● 18	
Total:		49		100 %


SCORING SUMMARY

Finding group	Finding	Finding score	Significant	Max score
Streptococcus pyogenes (group A)				4
	β-haemolytic streptococcus, Group A	3	1	4
	Streptococcus pyogenes	3	1	4
Total:				4

Sample S003 | Negative/normal flora

Throat streptococcal culture (5140)

Sample S003 Negative/normal flora



LABORATORY SPECIFIC SCORING TABLE

Finding group	Finding	Clinical significance	Own score	Max score	Own success rate	Difference	AVR success rate
Negative/normal flora	Negative / normal flora	Clinically not significant	4	4	100 %	4.1 %	95.9 %
Total:			4	4	100 %	4.1 %	95.9 %

REPORT TO THE CLINICIAN

Finding group	Finding	Finding count	Significant	Non significant	AVR success rate
Negative/normal flora		49			95.9 %
	<input checked="" type="radio"/> Negative / normal flora	47	3	<input checked="" type="radio"/> 44	
	<input type="radio"/> B-haemolytic streptococcus, sent for referral	1	1		
	<input type="radio"/> B-haemolytic streptococcus, Group C	1	1		
Total:		49			95.9 %

SCORING SUMMARY

Finding group	Finding	Finding score	Max score
Negative/normal flora			4
	Negative / normal flora	4	4
	B-haemolytic streptococcus, sent for referral	0	4
	B-haemolytic streptococcus, Group C	0	4
Total:			4

Report Info**PARTICIPANTS**

Altogether 56 laboratories from 10 countries participated in this EQA round.

REPORT INFO

On the front page you can see summaries of overall success rate and sample specific success rates which have been calculated from the scores. The reported results and the scores are presented in the same report but in separate tables.

In general, the expected results are marked with green color. Accepted results may also be indicated with yellow color. Laboratory's own results are indicated with a black radio button . In the participant specific report there is also a laboratory specific scoring table for each sample, where you can find your own result and the scores given.

If you have not reported results you will get a note: "You have not responded in time, only global report is available".

For information on report interpretation and performance evaluation, please see the "EQAS Interpretation guidelines" in LabScala User instructions. In case you have any questions regarding the reports, please contact the EQA Coordinator.

SCORING

The results in the "Report to the clinician" part can be scored when at least 60% of the participants have reported the correct/expected result and when there are at least three reported results. The report includes a sample specific scoring summary.

Laboratory's scores have been converted to percentage (own success rate, % from maximum scores) with a target at 100%. Own success rate is compared with the success rate of all results.

The following general rules are applied:

4 points is reached by reporting the expected result

1-3 points is given to results that are partly correct/insufficient regarding the expected finding

0 points is given for an incorrect/false result


Client report

	No of participants	No of responded participants	Response percentage
Throat streptococcal culture, March, 1-2023	51	49	96.1 %
Throat streptococcal culture, screening, March, 1-2023	5	3	60 %


Sample S001 | Negative/normal flora

Sample S001 results	Responded	Count
	Haemolysis	42
	Bacitracin test	5
	Agglutination test	24
	Identification tests: NAT	1
	Total:	72

Sample S001 Haemolysis, Negative/normal flora



Sample S001 Bacitracin test, Negative/normal flora




HAEMOLYSIS

Finding group	Result	Result count
Negative/normal flora		42
	No β-haemolytic colonies	13
	β-haemolytic colonies	29
Total:		42

BACITRACIN TEST

Finding group	Result	Result count
Negative/normal flora		5
	Resistant	5
Total:		5

Sample S001 Agglutination test, Negative/normal flora




AGGLUTINATION TEST

Finding group	Method	Group B	Group C	Total:
Negative/normal flora				24

	Microscreen Strep Grouping Latex (Microgen Bioproducts)	1	1	2
	Oxoid Streptococcal Grouping kit (Thermo Fisher Scientific)	10	-	10
	Pastorex Strep (BioRad)	3	-	3
	Prolex Streptococc. Grouping Latex kit (Pro-Lab)	3	-	3
	Remel PathoDx Strep Grouping (Thermo Fisher Scientific)	1	-	1
	Remel PathoDextra Strep Grouping (Thermo Fisher Scientific)	4	-	4
	Remel Streptex Latex Agglutination Test (Thermo Fisher Scientific)	1	-	1
	Total:	23	1	24

Sample S001 Identification tests:
NAT, Negative/normal flora




IDENTIFICATION TESTS: NAT

Finding group	Method	Result	Result count
Negative/normal flora	Quidel Solana Strep Complete Assay	Negative	1
Total:			1


Sample S002 | Streptococcus pyogenes (group A)

Sample S002 results	Responded	Count
	Haemolysis	51
	Bacitracin test	14
	Agglutination test	34
	Identification tests: MALDI-TOF	28
	Commercial identification kits and analyzers	4
	Identification tests: NAT	1
	Total:	132

Sample S002 Haemolysis, Streptococcus pyogenes (group A)



Sample S002 Bacitracin test, Streptococcus pyogenes (group A)




HAEMOLYSIS

Finding group	Result	Result count
Streptococcus pyogenes (group A)	No β-haemolytic colonies	1
	<input checked="" type="radio"/> β-haemolytic colonies	50
	Total:	51

BACITRACIN TEST

Finding group	Result	Result count
Streptococcus pyogenes (group A)	Sensitive	13
	Resistant	1
	Total:	14


Sample S002 Agglutination test, Streptococcus pyogenes (group A)



AGGLUTINATION TEST


Finding group	Method	Group A	Group C	Total:
Streptococcus pyogenes (group A)				34
	Microscreen Strep Grouping Latex (Microgen Bioproducts)	2	-	2
	Oxoid Streptococcal Grouping kit (Thermo Fisher Scientific)	13	-	13
	Pastorex Strep (BioRad)	4	-	4
	Prolex Streptococc. Grouping Latex kit (Pro-Lab)	4	-	4
	Remel PathoDx Strep Grouping (Thermo Fisher Scientific)	1	-	1
	Remel PathoDextra Strep Grouping (Thermo Fisher Scientific)	5	1	6
	Remel Streptex Latex Agglutination Test (Thermo Fisher Scientific)	3	-	3
	Streptococcal Grouping Latex Test (Plasmatec)	1	-	1
	Total:	33	1	34

Sample S002 Identification tests: MALDI-TOF, Streptococcus pyogenes (group A)



Streptococcus pyogenes
Streptococcus dysgalactiae

Sample S002 Commercial identification kits and analyzers, Streptococcus pyogenes (group A)



Streptococcus pyogenes


IDENTIFICATION TESTS: MALDI-TOF

Finding group	Method	Result	Score / Probability %	Score / Probability % count
Streptococcus pyogenes (group A)	Autof MALDI-ToF (Chirus)	Streptococcus pyogenes	9.5..10	1
	MALDI Biotyper (Bruker)	Streptococcus pyogenes	⊙ ≥2	15
		Streptococcus dysgalactiae	≥2	1
	VITEK MS (bioMérieux)	Streptococcus pyogenes	99,9 %	10
				99 %
Total:				28

COMMERCIAL IDENTIFICATION KITS AND ANALYZERS

Finding group	Method	Result	Profile number	Profile number count
Streptococcus pyogenes (group A)	VITEK 2 (bioMérieux)	Streptococcus pyogenes	051412360313271	1
	VITEK 2 Compact 15 (bioMérieux)	Streptococcus pyogenes	051412360311231	1
	VITEK 2 Compact 60 (bioMérieux)	Streptococcus pyogenes	16597	1
			N/A	1
Total:				4

Sample S002 Identification tests:
NAT, Streptococcus pyogenes (group A)




IDENTIFICATION TESTS: NAT

Finding group	Method	Result	Result count
Streptococcus pyogenes (group A)	Quidel Solana Strep Complete Assay	Streptococcus pyogenes	1
Total:			1


Sample S003 | Negative/normal flora

Sample S003 results	Responded	Count
	Haemolysis	39
	Bacitracin test	2
	Agglutination test	3
	Identification tests: NAT	1
	Total:	45

Sample S003 Haemolysis, Negative/normal flora



Sample S003 Bacitracin test, Negative/normal flora



■ No β-haemolytic colonies
■ Indeterminate
■ β-haemolytic colonies

■ Resistant

HAEMOLYSIS

Finding group	Result	Result count
Negative/normal flora		39
	No β-haemolytic colonies	34
	β-haemolytic colonies	4
	Indeterminate	1
Total:		39

BACITRACIN TEST

Finding group	Result	Result count
Negative/normal flora		2
	Resistant	2
Total:		2

Sample S003 Agglutination test, Negative/normal flora




■ Group C ■ Group D

AGGLUTINATION TEST

Finding group	Method	Group C	Group D	Total:
---------------	--------	---------	---------	--------

Negative/normal flora				3
	Microscreen Strep Grouping Latex (Microgen Bioproducts)	1	1	2
	Pastorex Strep (BioRad)	-	1	1
	Total:	1	2	3

Sample S003 Identification tests:
NAT, Negative/normal flora



■ Negative

IDENTIFICATION TESTS: NAT

Finding group	Method	Result	Result count
Negative/normal flora	Quidel Solana Strep Complete Assay	Negative	1
Total:			1


GLOBAL REPORT

	No of participants	No of responded participants	Response percentage
Throat streptococcal culture, March, 1-2023	51	49	96.1 %
Throat streptococcal culture, screening, March, 1-2023	5	3	60 %

Summary

Throat streptococcal culture (5140)


Overall success rate by samples



Summary	AVR success rate
Sample S001	93.9 %
Sample S002	100 %
Sample S003	95.9 %
Average:	96.6 %

Throat streptococcal culture, screening (5141)

Overall success rate by samples




Summary	AVR success rate
Sample S001	83.3 %
Sample S002	100 %
Sample S003	100 %
Average:	94.4 %

Sample S001 | Negative/normal flora

Throat streptococcal culture (5140)

Sample S001 Negative/normal flora



REPORT TO THE CLINICIAN


Finding group	Finding	Finding count	Significant	Non significant	AVR success rate
Negative/normal flora		49			93.9 %
	Negative / normal flora	46	3	43	
	β-haemolytic streptococcus, sent for referral	2	2		
	β-haemolytic streptococcus, Group C	1	1		
Total:		49			93.9 %

SCORING SUMMARY

Finding group	Finding	Finding score	Max score
Negative/normal flora			4
	Negative / normal flora	4	4
	β-haemolytic streptococcus, sent for referral	0	4
	β-haemolytic streptococcus, Group C	0	4
Total:			4

Throat streptococcal culture, screening (5141)

Sample S001 Negative/normal flora



REPORT TO THE CLINICIAN

Finding group	Finding	Finding count	Referred	Not referred	AVR success rate
Negative/normal flora		3			83.3 %
	Negative / normal flora	2		2	
	β-haemolytic streptococcus	1	1		
Total:		3			83.3 %


SCORING SUMMARY

Finding group	Finding	Finding score	Referred	Max score
Negative/normal flora				4
	Negative / normal flora	4		4
	β-haemolytic streptococcus	1	1	4
Total:				4

Sample S002 | Streptococcus pyogenes (group A)

Throat streptococcal culture (5140)

Sample S002 Streptococcus pyogenes (group A)



REPORT TO THE CLINICIAN


Finding group	Finding	Finding count	Significant	AVR success rate
Streptococcus pyogenes (group A)		49		100 %
	β-haemolytic streptococcus, Group A	31	31	
	Streptococcus pyogenes	18	18	
Total:		49		100 %

SCORING SUMMARY

Finding group	Finding	Finding score	Significant	Max score
Streptococcus pyogenes (group A)				4
	β-haemolytic streptococcus, Group A	3	1	4
	Streptococcus pyogenes	3	1	4
Total:				4

Throat streptococcal culture, screening (5141)

Sample S002 Streptococcus pyogenes (group A)



REPORT TO THE CLINICIAN

Finding group	Finding	Finding count	Referred	Not referred	AVR success rate
Streptococcus pyogenes (group A)		3			100 %
	Possible group A	3	2	1	

Total:		3			100 %
--------	--	---	--	--	-------


SCORING SUMMARY

Finding group	Finding	Finding score	Referred	Not referred	Max score
Streptococcus pyogenes (group A)					4
	Possible group A	3	1	1	4
Total:					4

Sample S003 | Negative/normal flora

Throat streptococcal culture (5140)

Sample S003 Negative/normal flora



REPORT TO THE CLINICIAN


Finding group	Finding	Finding count	Significant	Non significant	AVR success rate
Negative/normal flora		49			95.9 %
	Negative / normal flora	47	3	44	
	β-haemolytic streptococcus, sent for referral	1	1		
	β-haemolytic streptococcus, Group C	1	1		
Total:		49			95.9 %

SCORING SUMMARY

Finding group	Finding	Finding score	Max score
Negative/normal flora			4
	Negative / normal flora	4	4
	β-haemolytic streptococcus, sent for referral	0	4
	β-haemolytic streptococcus, Group C	0	4
Total:			4

Throat streptococcal culture, screening (5141)

Sample S003 Negative/normal flora



REPORT TO THE CLINICIAN

Finding group	Finding	Finding count	Not referred	AVR success rate
---------------	---------	---------------	--------------	------------------

Negative/normal flora		3		100 %
	Negative / normal flora	3	3	
Total:		3		100 %

SCORING SUMMARY

Finding group	Finding	Finding score	Max score
Negative/normal flora			4
	Negative / normal flora	4	4
Total:			4

Report Info**PARTICIPANTS**

Altogether 56 laboratories from 10 countries participated in this EQA round.

REPORT INFO

On the front page you can see summaries of overall success rate and sample specific success rates which have been calculated from the scores. The reported results and the scores are presented in the same report but in separate tables.

In general, the expected results are marked with green color. Accepted results may also be indicated with yellow color. Laboratory's own results are indicated with a black radio button . In the participant specific report there is also a laboratory specific scoring table for each sample, where you can find your own result and the scores given.

If you have not reported results you will get a note: "You have not responded in time, only global report is available".

For information on report interpretation and performance evaluation, please see the "EQAS Interpretation guidelines" in LabScala User instructions. In case you have any questions regarding the reports, please contact the EQA Coordinator.

SCORING

The results in the "Report to the clinician" part can be scored when at least 60% of the participants have reported the correct/expected result and when there are at least three reported results. The report includes a sample specific scoring summary.

Laboratory's scores have been converted to percentage (own success rate, % from maximum scores) with a target at 100%. Own success rate is compared with the success rate of all results.

The following general rules are applied:

4 points is reached by reporting the expected result

1-3 points is given to results that are partly correct/insufficient regarding the expected finding

0 points is given for an incorrect/false result


GLOBAL REPORT

	No of participants	No of responded participants	Response percentage
Throat streptococcal culture, March, 1-2023	51	49	96.1 %
Throat streptococcal culture, screening, March, 1-2023	5	3	60 %


Sample S001 | Negative/normal flora

Sample S001 results	Responded	Count
	Haemolysis	42
	Bacitracin test	5
	Agglutination test	24
	Identification tests: NAT	1
	Total:	72

Sample S001 Haemolysis, Negative/normal flora



Sample S001 Bacitracin test, Negative/normal flora




HAEMOLYSIS

Finding group	Result	Result count
Negative/normal flora		42
	No β-haemolytic colonies	13
	β-haemolytic colonies	29
Total:		42

BACITRACIN TEST

Finding group	Result	Result count
Negative/normal flora		5
	Resistant	5
Total:		5

Sample S001 Agglutination test, Negative/normal flora



AGGLUTINATION TEST

Finding group	Method	Group B	Group C	Total:
Negative/normal flora				24

	Microscreen Strep Grouping Latex (Microgen Bioproducts)	1	1	2
	Oxoid Streptococcal Grouping kit (Thermo Fisher Scientific)	10	-	10
	Pastorex Strep (BioRad)	3	-	3
	Prolex Streptococc. Grouping Latex kit (Pro-Lab)	3	-	3
	Remel PathoDx Strep Grouping (Thermo Fisher Scientific)	1	-	1
	Remel PathoDextra Strep Grouping (Thermo Fisher Scientific)	4	-	4
	Remel Streptex Latex Agglutination Test (Thermo Fisher Scientific)	1	-	1
	Total:	23	1	24

Sample S001 Identification tests:
NAT, Negative/normal flora



■ Negative


IDENTIFICATION TESTS: NAT

Finding group	Method	Result	Result count
Negative/normal flora	Quidel Solana Strep Complete Assay	Negative	1
Total:			1

Sample S002 | Streptococcus pyogenes (group A)


Sample S002 results	Responded	Count
	Haemolysis	51
	Bacitracin test	14
	Agglutination test	34
	Identification tests: MALDI-TOF	28
	Commercial identification kits and analyzers	4
	Identification tests: NAT	1
	Total:	132

Sample S002 Haemolysis, Streptococcus pyogenes (group A)



■ No β-haemolytic colonies ■ β-haemolytic colonies

Sample S002 Bacitracin test, Streptococcus pyogenes (group A)



■ Sensitive ■ Resistant


HAEMOLYSIS

Finding group	Result	Result count
Streptococcus pyogenes (group A)		51
	No β-haemolytic colonies	1
	β-haemolytic colonies	50
Total:		51

BACITRACIN TEST

Finding group	Result	Result count
Streptococcus pyogenes (group A)		14
	Sensitive	13
	Resistant	1
Total:		14

Sample S002 Agglutination test, Streptococcus pyogenes (group A)




■ Group A ■ Group C

AGGLUTINATION TEST


Finding group	Method	Group A	Group C	Total:
Streptococcus pyogenes (group A)				34
	Microscreen Strep Grouping Latex (Microgen Bioproducts)	2	-	2
	Oxoid Streptococcal Grouping kit (Thermo Fisher Scientific)	13	-	13
	Pastorex Strep (BioRad)	4	-	4
	Prolex Streptococc. Grouping Latex kit (Pro-Lab)	4	-	4
	Remel PathoDx Strep Grouping (Thermo Fisher Scientific)	1	-	1
	Remel PathoDextra Strep Grouping (Thermo Fisher Scientific)	5	1	6
	Remel Streptex Latex Agglutination Test (Thermo Fisher Scientific)	3	-	3
	Streptococcal Grouping Latex Test (Plasmatec)	1	-	1
	Total:	33	1	34

Sample S002 Identification tests: MALDI-TOF, Streptococcus pyogenes (group A)



Streptococcus pyogenes
Streptococcus dysgalactiae

Sample S002 Commercial identification kits and analyzers, Streptococcus pyogenes (group A)



Streptococcus pyogenes


IDENTIFICATION TESTS: MALDI-TOF

Finding group	Method	Result	Score / Probability %	Score / Probability % count
Streptococcus pyogenes (group A)	Autof MALDI-ToF (Chirus)	Streptococcus pyogenes	9.5..10	1
	MALDI Biotyper (Bruker)	Streptococcus pyogenes	≥2	15
		Streptococcus dysgalactiae	≥2	1
	VITEK MS (bioMérieux)	Streptococcus pyogenes	99,9 %	10
				99 %
Total:				28

COMMERCIAL IDENTIFICATION KITS AND ANALYZERS

Finding group	Method	Result	Profile number	Profile number count
Streptococcus pyogenes (group A)	VITEK 2 (bioMérieux)	Streptococcus pyogenes	051412360313271	1
	VITEK 2 Compact 15 (bioMérieux)	Streptococcus pyogenes	051412360311231	1
	VITEK 2 Compact 60 (bioMérieux)	Streptococcus pyogenes	16597	1
			N/A	1
Total:				4

Sample S002 Identification tests:
 NAT, Streptococcus pyogenes (group
 A)




IDENTIFICATION TESTS: NAT

Finding group	Method	Result	Result count
Streptococcus pyogenes (group A)	Quidel Solana Strep Complete Assay	Streptococcus pyogenes	1
Total:			1


Sample S003 | Negative/normal flora

Sample S003 results	Responded	Count
	Haemolysis	39
	Bacitracin test	2
	Agglutination test	3
	Identification tests: NAT	1
	Total:	45

Sample S003 Haemolysis, Negative/normal flora



Sample S003 Bacitracin test, Negative/normal flora



■ No β-haemolytic colonies
 ■ β-haemolytic colonies
■ Indeterminate

■ Resistant

HAEMOLYSIS

Finding group	Result	Result count
Negative/normal flora	No β-haemolytic colonies	34
	β-haemolytic colonies	4
	Indeterminate	1
	Total:	39

BACITRACIN TEST

Finding group	Result	Result count
Negative/normal flora	Resistant	2
	Total:	2

Sample S003 Agglutination test, Negative/normal flora




■ Group C ■ Group D

AGGLUTINATION TEST

Finding group	Method	Group C	Group D	Total:

Negative/normal flora				3
	Microscreen Strep Grouping Latex (Microgen Bioproducts)	1	1	2
	Pastorex Strep (BioRad)	-	1	1
	Total:	1	2	3

Sample S003 Identification tests:
NAT, Negative/normal flora



■ Negative

IDENTIFICATION TESTS: NAT

Finding group	Method	Result	Result count
Negative/normal flora	Quidel Solana Strep Complete Assay	Negative	1
Total:			1

External Quality Assessment Scheme

Throat streptococcal culture Round 1, 2023

Specimens

The round included three lyophilized samples. The sample lots were tested in an accredited Finnish reference laboratory and the results were consistent with the certificates provided by the sample manufacturer. Based on the quality controls conducted by the sample material manufacturer, pre-testing and the results obtained in the round, the sample lots are to be considered as homogeneous, stable and suitable for external quality assessment. The materials were sent without temperature control packaging.

The use of samples only for external quality assessment. The consent of Labquality must be requested for the use of the microbial strains contained in the samples for other purposes.

The content of the samples was as follows:

Sample S001 (LQ761523011)
Streptococcus agalactiae (group B) C060708
Staphylococcus aureus C020316
Streptococcus viridans C020203

Sample S002 (LQ761523012)
Streptococcus pyogenes (group A) ATCC® 19615™
Staphylococcus aureus C020316
Escherichia coli C1

Sample S003 (LQ761523013)
Streptococcus viridans C020203
Staphylococcus aureus C020316
Enterococcus faecalis C090604

Report info

Please see the description of the data analysis on the last page of the laboratory-specific reports and global reports. The results reported from products 5140 and 5141 (a separate scheme for Finnish screening laboratories) are presented in the same reports. It is important to read the Final report first, because it contains important information of the samples and results in each round.

Comments – Expert

Sample S001: Negative/normal flora

The expected result was reported by 46/49 (94%) of the participating laboratories. Except for a couple of mistakes, a good result.

Sample S002: *Streptococcus pyogenes* (group A)

The result “Group A” or “*Streptococcus pyogenes*” was reported by all (49/49) participating laboratories.

Sample S003: Negative/normal flora

Also, for this negative sample, the expected result was reported by almost all 47/49 (96%) of the participating laboratories. A good result!

Exceptions in scoring

No exceptions.

End of report

2023-03-28

FINAL REPORT

Product no. 5140

Subcontracting: Sample pretesting

Samples sent	2023-02-28
Round closed	2023-03-23
Expected results	2023-03-28
Final report	2023-03-28

Request for correction

Typing errors in laboratory's result forms are on laboratory's responsibility. Labquality accepts responsibility only for result processing. Requests must be notified by writing within three weeks from the date of this letter.

Authorized by

EQA Coordinator
Jaana Paakkanen
jaana.paakkanen@labquality.fi

Expert

MD, PhD, professor
Hannu Sarkkinen,
Lahti, Finland

Labquality Oy

Kumpulantie 15
FI-00520 HELSINKI
Finland

Tel. + 358 9 8566 8200

Fax + 358 9 8566 8280

info@labquality.fi

www.labquality.com



Copyright © Labquality Oy

Labquality does not permit any reproduction for commercial purposes of any portion of the material subject to this copyright. Labquality prohibits any use of its name, or reference to Labquality EQA program, or material in this report in any advertising, brochures or other commercial publications. Labquality EQA data do not necessarily indicate the superiority of instruments, reagents, testing equipments or materials used by participating laboratories. Use of Labquality EQA data to suggest superiority or inferiority of equipments or materials may be deceptive and misleading. Proficiency test results are handled confidentially. Labquality will not issue any statements to third parties of the performance of laboratories in external quality assessment schemes unless otherwise agreed.